Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShieh, PB-
dc.contributor.authorKuntz, NL-
dc.contributor.authorDowling, JJ-
dc.contributor.authorMüller-Felber, W-
dc.contributor.authorBönnemann, CG-
dc.contributor.authorSeferian, AM-
dc.contributor.authorServais, L-
dc.contributor.authorSmith, BK-
dc.contributor.authorMuntoni, F-
dc.contributor.authorBlaschek, A-
dc.contributor.authorFoley, AR-
dc.contributor.authorSaade, DN-
dc.contributor.authorNeuhaus, S-
dc.contributor.authorAlfano, LN-
dc.contributor.authorBeggs, AH-
dc.contributor.authorBuj-Bello, A-
dc.contributor.authorChilders, MK-
dc.contributor.authorDuong, T-
dc.contributor.authorGraham, RJ-
dc.contributor.authorJain, M-
dc.contributor.authorCoats, J-
dc.contributor.authorMacBean, V-
dc.contributor.authorJames, ES-
dc.contributor.authorLee, J-
dc.contributor.authorMavilio, F-
dc.contributor.authorMiller, W-
dc.contributor.authorVarfaj, F-
dc.contributor.authorMurtagh, M-
dc.contributor.authorHan, C-
dc.contributor.authorNoursalehi, M-
dc.contributor.authorLawlor, MW-
dc.contributor.authorPrasad, S-
dc.contributor.authorRico, S-
dc.identifierORCID iD: Vicky MacBean
dc.identifier.citationShieh, P.B. et al. (2023) 'Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial', The Lancet Neurology, 22 (12), pp. 1125 - 1139. doi: 10.1016/s1474-4422(23)00313-7.en_US
dc.descriptionData sharing: Researchers may request access to anonymised participant-level data, trial-level data, and protocols from clinical trials sponsored by Astellas Gene Therapies at For the Astellas criteria on data sharing see
dc.descriptionSupplementary Materials are available online at: .-
dc.description.abstractCopyright © 2023 The Author(s).. Background: X-linked myotubular myopathy is a rare, life-threatening, congenital muscle disease observed mostly in males, which is caused by mutations in MTM1. No therapies are approved for this disease. We aimed to assess the safety and efficacy of resamirigene bilparvovec, which is an adeno-associated viral vector serotype 8 delivering human MTM1. Methods: ASPIRO is an open-label, dose-escalation trial at seven academic medical centres in Canada, France, Germany, and the USA. We included boys younger than 5 years with X-linked myotubular myopathy who required mechanical ventilator support. The trial was initially in two parts. Part 1 was planned as a safety and dose-escalation phase in which participants were randomly allocated (2:1) to either the first dose level (1·3 × 1014 vector genomes [vg]/kg bodyweight) of resamirigene bilparvovec or delayed treatment, then, for later participants, to either a higher dose (3·5 × 1014 vg/kg bodyweight) of resamirigene bilparvovec or delayed treatment. Part 2 was intended to confirm the dose selected in part 1. Resamirigene bilparvovec was administered as a single intravenous infusion. An untreated control group comprised boys who participated in a run-in study (INCEPTUS; NCT02704273) or those in the delayed treatment cohort who did not receive any dose. The primary efficacy outcome was the change from baseline to week 24 in hours of daily ventilator support. After three unexpected deaths, dosing at the higher dose was stopped and the two-part feature of the study design was eliminated. Because of changes to the study design during its implementation, analyses were done on an as-treated basis and are deemed exploratory. All treated and control participants were included in the safety analysis. The trial is registered with, NCT03199469. Outcomes are reported as of Feb 28, 2022. ASPIRO is currently paused while deaths in dosed participants are investigated. Findings: Between Aug 3, 2017 and June 1, 2021, 30 participants were screened for eligibility, of whom 26 were enrolled; six were allocated to the lower dose, 13 to the higher dose, and seven to delayed treatment. Of the seven children whose treatment was delayed, four later received the higher dose (n=17 total in the higher dose cohort), one received the lower dose (n=7 total in the lower dose cohort), and two received no dose and joined the control group (n=14 total, including 12 children from INCEPTUS). Median age at dosing or enrolment was 12·1 months (IQR 10·0–30·9; range 9·5–49·7) in the lower dose cohort, 31·1 months (16·0–64·7; 6·8–72·7) in the higher dose cohort, and 18·7 months (10·1–31·5; 5·9–39·3) in the control cohort. Median follow-up was 46·1 months (IQR 41·0–49·5; range 2·1–54·7) for lower dose participants, 27·6 months (24·6–29·1; 3·4–41·0) for higher dose participants, and 28·3 months (9·7–46·9; 5·7–32·7) for control participants. At week 24, lower dose participants had an estimated 77·7 percentage point (95% CI 40·22 to 115·24) greater reduction in least squares mean hours per day of ventilator support from baseline versus controls (p=0·0002), and higher dose participants had a 22·8 percentage point (6·15 to 39·37) greater reduction from baseline versus controls (p=0·0077). One participant in the lower dose cohort and three in the higher dose cohort died; at the time of death, all children had cholestatic liver failure following gene therapy (immediate causes of death were sepsis; hepatopathy, severe immune dysfunction, and pseudomonal sepsis; gastrointestinal haemorrhage; and septic shock). Three individuals in the control group died (haemorrhage presumed related to hepatic peliosis; aspiration pneumonia; and cardiopulmonary failure). Interpretation: Most children with X-linked myotubular myopathy who received MTM1 gene replacement therapy had important improvements in ventilator dependence and motor function, with more than half of dosed participants achieving ventilator independence and some attaining the ability to walk independently. Investigations into the risk for underlying hepatobiliary disease in X-linked myotubular myopathy, and the need for monitoring of liver function before gene replacement therapy, are ongoing.en_US
dc.description.sponsorshipAstellas Gene Therapies.en_US
dc.format.extent1125 - 1139-
dc.rightsCopyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license (
dc.titleSafety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trialen_US
dc.relation.isPartOfThe Lancet Neurology-
dc.rights.holderThe Author(s)-
Appears in Collections:Dept of Health Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license ( kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons